Maze Therapeutics MAZE
Maze Therapeutics reported a $47.97 million net loss
Maze Therapeutics (MAZE) filed a 10-Q with the SEC on Nov 9, 2026, 4:15 pm ET. Source: the filing on SEC EDGAR.
Quarterly report, 4 new risk factors
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001193125-26-453619
- Revenue of $20 million for the three months ended Sep 30, 2026
- Net loss of $47.97 million for the three months ended Sep 30, 2026
- Diluted EPS of -$0.79 for the three months ended Sep 30, 2026
- Cash and equivalents of $154.16 million as of Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
4 new risk factors · 1 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $0 | $0 | — |
| Operating income and margin | −$51.52M | −$48.04M | −7.2% |
| Net income | −$47.97M | −$44.73M | −7.2% |
| Operating cash flow | −$32.84M | −$15.05M | −118% |
| Cash | $154.16M | $202.64M | −24% |
New risk factors (4)
- Further, we rely on third parties located in China for some of our contract manufacturing, and we expect to continue to use such third-party manufacturers for such purposes. For any activities conducted in China, we are exposed to the possibility of product supply disruption and increased costs in the event of… +1 more paragraph
- ANDA applications for proposed generic versions of any small molecule products for which we obtain approval four or five years from the date of such approval was granted.
- On September 30, 2026, CMS released the final rule for the first proposal, the Global Benchmark for Efficient Drug Pricing Model, or GLOBE, for Medicare Part B, which requires manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices… +1 more paragraph
- In addition, the U.S. Department of Justice's rule implementing Executive Order 14117, the requirements of which are now fully in effect, prohibits or restricts certain transactions that could result in access by "countries of concern," including China, or covered persons associated with them, to bulk U.S. sensitive…
Removed risk factors (1)
- Further, we rely on third parties located in China for some of our contract manufacturing, and we expect to continue to use such third-party manufacturers for such purposes. For any activities conducted in China, we are exposed to the possibility of product supply disruption and increased costs in the event of…